Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

20.11.24	Sanofi: Information concerning the total number of voting rights and shares - October 2024 (GlobeNewswire)
15.11.24	Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria (RTTNews)
15.11.24	Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (GlobeNewswire)
14.11.24	Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma (GlobeNewswire)
06.11.24	Regeneron: EC Approves Dupixent For Young Children With EoE (RTTNews)
06.11.24	Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis (GlobeNewswire)
29.10.24	Sanofi Launches Beyfortus Immunization Against RSV For Infants In Canada This Fall (RTTNews)
25.10.24	Sanofi Q3 Profit Rises - Quick Facts (RTTNews)
25.10.24	Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance (GlobeNewswire)
24.10.24	Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI (GlobeNewswire)
21.10.24	Sanofi Enters Exclusive Negotiations To Sell 50% Stake In Opella To CD&R (RTTNews)
21.10.24	Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare (GlobeNewswire)
17.10.24	PAI Partners Raises Offer For Sanofi's Consumer Health Biz Opella: Reports (RTTNews)
17.10.24	Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines (GlobeNewswire)
17.10.24	Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines (GlobeNewswire)
16.10.24	FDA Updates Sanofi's FLUBLOK Vaccine Label With New Safety Data For Pregnant Individuals (RTTNews)
15.10.24	Sanofi: Information concerning the total number of voting rights and shares - September 2024 (GlobeNewswire)
11.10.24	Press Release: Sanofi in discussions to sell a controlling stake in Opella (GlobeNewswire)
09.10.24	Sanofi : Beyfortus Data Reinforce Effectiveness Against RSV Disease & Hospitalization In Infants (RTTNews)
09.10.24	Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants (GlobeNewswire)
27.09.24	Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment (RTTNews)
27.09.24	Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD (GlobeNewswire)
27.09.24	Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease (RTTNews)
27.09.24	Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD (GlobeNewswire)
26.09.24	Press Release: Availability of the Q3 2024 Aide mémoire (GlobeNewswire)
21.09.24	Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for trans (GlobeNewswire)
20.09.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old (EN, Sanofi-Aventis)
20.09.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old (GlobeNewswire)
20.09.24	Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study (GlobeNewswire)
20.09.24	Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study (EN, Sanofi-Aventis)
16.09.24	Sanofi: Information concerning the total number of voting rights and shares - August 2024 (GlobeNewswire)
16.09.24	Sanofi To Offer BEYFORTUS Doses To Protect Babies During RSV Season - Quick Facts (RTTNews)
12.09.24	Sanofi, RadioMedix, Orano Med Sign Deal For Next-Gen Radioligand Medicine For Rare Cancers (RTTNews)
12.09.24	Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers (GlobeNewswire)
12.09.24	Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers (EN, Sanofi-Aventis)
11.09.24	Sanofi, Regeneron: ADEPT Study Of Dupixent In Bullous Pemphigoid Meets Endpoints (RTTNews)
11.09.24	Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU (EN, Sanofi-Aventis)
11.09.24	Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU (GlobeNewswire)
11.09.24	Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study (EN, Sanofi-Aventis)
11.09.24	Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study (GlobeNewswire)
10.09.24	Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies (EN, Sanofi-Aventis)
02.09.24	Sanofi: Tolebrutinib For NrSPMS Meets Primary Goal In HERCULES Trial; Fails In GEMINI Trial For RMS (RTTNews)
02.09.24	Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis (EN, Sanofi-Aventis)
02.09.24	Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis (GlobeNewswire)
02.09.24	Biotech Stocks Facing FDA Decision In September 2024 (RTTNews)
26.08.24	Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases (EN, Sanofi-Aventis)
09.08.24	Sanofi: Information concerning the total number of voting rights and shares - July 2024 (GlobeNewswire)
08.08.24	Sanofi : Sarclisa Induction Treatment Improves PFS In Transplant-Eligible Myeloma Patients (RTTNews)
08.08.24	Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant (EN, Sanofi-Aventis)
08.08.24	Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus
22.11.24		Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge
22.11.24		Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500
22.11.24		Gewinne in New York: NASDAQ 100 präsentiert sich fester
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus